Press release 📈 Stocks 🌍 United States

MetaVia Reports DA-1726 Preclinical Data Showing Weight Loss Parity vs Retatrutide

MetaVia's DA-1726 demonstrated comparable weight loss to retatrutide in preclinical trials with less appetite suppression, bolstering the company's strategy for a 2027 Phase 2 launch in liver-related metabolic diseases.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: MTVA ↑ 3/10 (55% confidence).

📊 Affected Assets (1)

MTVA
Bullish 🤖 55%
📅 Short-term 🌍 US · Explicit

MetaVia's own release cites quantified preclinical head-to-head data: DA-1726 cut plasma glucose by 43.0%/39.2% vs 21.5%/32.5% for retatrutide and matched weight loss (41.7% vs 43.6%) with less food-intake suppression, plus higher hepatic FGF21. This supports the differentiated liver-focused profile and the planned Phase 2 in MetALD/ALD in H2 2027, but the data are from obese mice, not humans, so the price effect is limited. The Phase 1 figures (13.5% weight, 68.0% liver fat reduction) are restatements of earlier clinical data.

Catalysts
  • ▲ Positive head-to-head preclinical data presented at ObesityWeek 2026 on November 14, 2026
  • ▲ Phase 2 study in MetALD and ALD targeted to begin in the second half of 2027
Risk Factors
  • ▼ Data are preclinical (diet-induced obese mice) and may not translate to humans
  • ▼ Phase 2 start is still roughly a year away, so no near-term clinical catalysts

🧭 Full analysis of these assets

🎯 Key Takeaways

  • DA-1726 achieved weight loss of 41.7% in high-dose mice, comparable to the 43.6% observed with retatrutide.
  • Plasma glucose levels decreased by 43.0% and 39.2% for DA-1726, outperforming retatrutide's 21.5% and 32.5% reductions.
  • DA-1726 reduced food intake by 19.6% and 31.2%, significantly less than the 36.7% and 41.4% suppression seen with retatrutide.
  • MetaVia plans to launch a 48-week Phase 2 study for DA-1726 in MetALD and ALD in the second half of 2027.

📝 Executive Summary

MetaVia Inc. presented preclinical data at ObesityWeek 2026 showing its dual-agonist DA-1726 achieved weight loss comparable to retatrutide in obese mice while requiring less food-intake suppression. The study highlighted DA-1726's ability to increase hepatic FGF21 expression and thermogenesis, supporting the company's plan to initiate a Phase 2 study in MetALD and ALD in the second half of 2027.

❓ FAQ

Does this new data change MetaVia's drug prospects?

The mouse study showed DA-1726 matched retatrutide on weight loss, lowered glucose more, and raised liver FGF21, supporting its liver-disease focus, but it is preclinical evidence only.

When is the next major step for DA-1726?

MetaVia plans to start a 48-week Phase 2 study in MetALD and ALD in the second half of 2027.